{"id":23927,"date":"2015-02-11T12:51:17","date_gmt":"2015-02-11T18:51:17","guid":{"rendered":"https:\/\/brakkeconsulting.com\/?p=23927"},"modified":"2018-04-16T09:45:08","modified_gmt":"2018-04-16T14:45:08","slug":"23927","status":"publish","type":"post","link":"https:\/\/brakkeconsulting.com\/pt\/23927\/","title":{"rendered":"RHI nomeia Brakke Consulting como agente exclusivo para eRapa (uma formula\u00e7\u00e3o de Rapamicina com patente pendente)"},"content":{"rendered":"<p>A RHI, uma empresa de desenvolvimento em est\u00e1gio inicial localizada em San Antonio, TX, nomeou a Brakke Consulting, Inc. de Dallas, TX para sua nova tecnologia de plataforma, eRapa, com direitos a um portf\u00f3lio completo de pedidos de patente. eRapa mostra grande promessa de ser o primeiro inibidor m-Tor da classe em medicina veterin\u00e1ria. Como um modulador imunol\u00f3gico citost\u00e1tico, eRapa tem um amplo espectro de benef\u00edcios potenciais, incluindo: regula\u00e7\u00e3o negativa do ciclo celular no c\u00e2ncer e autoimunidade, autofagia aprimorada que permite a remo\u00e7\u00e3o de detritos celulares ap\u00f3s trauma ou com envelhecimento avan\u00e7ado, patologia vascular aprimorada que permite maior fluxo sangu\u00edneo para idosos e \u00f3rg\u00e3os danificados e uma capacidade de refor\u00e7o imunol\u00f3gico em indiv\u00edduos saud\u00e1veis.<\/p>\n<p>O RHI demonstrou seguran\u00e7a e efic\u00e1cia de eRapa em tr\u00eas programas terap\u00eauticos piloto em c\u00e3es e gatos, incluindo Gengivoestomatite Cr\u00f4nica Felina (FCGS), Disfun\u00e7\u00e3o Cognitiva Canina (CCD) e Dist\u00farbio do Disco Intervertebral (IVDD). Um quarto ensaio cl\u00ednico em oncologia canina est\u00e1 em andamento. Est\u00e1 em curso a interface com o Centro de Medicina Veterin\u00e1ria.<\/p>\n<p>\u201cEstamos satisfeitos por ter a Brakke Consulting na equipe para nos ajudar a encontrar um parceiro para o desenvolvimento e comercializa\u00e7\u00e3o da Rapamicina\u201d, disse Randy Goldsmith, CEO da RHI.<\/p>\n<p>Para obter mais informa\u00e7\u00f5es sobre esta tecnologia, entre em contato com o Dr. David Goodnight em 830-285-1259 ou Ron Brakke em 972-243-4033.&nbsp;<\/p>\n<p><u>Sobre a Brakke Consulting<\/u><br \/>\nPor mais de 28 anos, a Brakke Consulting oferece solu\u00e7\u00f5es abrangentes para a ind\u00fastria de sa\u00fade animal, incluindo marketing internacional, desenvolvimento de novos neg\u00f3cios, avalia\u00e7\u00e3o de produtos e estrat\u00e9gias de distribui\u00e7\u00e3o. A empresa \u00e9 conhecida por seus estudos de mercado sindicalizados, fornecendo informa\u00e7\u00f5es estrat\u00e9gicas e oportunas para o setor, e por seus servi\u00e7os de recrutamento personalizados.<\/p>\n<p><u>Declara\u00e7\u00f5es de Previs\u00e3o.<\/u>&nbsp; <br \/>\nEste comunicado de imprensa pode conter proje\u00e7\u00f5es ou outras declara\u00e7\u00f5es prospectivas sobre planos futuros, eventos ou desempenho. Todas as declara\u00e7\u00f5es que n\u00e3o sejam fatos e condi\u00e7\u00f5es presentes e hist\u00f3ricos contidas neste comunicado, incluindo quaisquer declara\u00e7\u00f5es sobre estrat\u00e9gia de neg\u00f3cios, estrat\u00e9gia regulat\u00f3ria, estrat\u00e9gia de marketing, planos e objetivos operacionais, resultados futuros de opera\u00e7\u00f5es ou posi\u00e7\u00f5es financeiras, s\u00e3o declara\u00e7\u00f5es prospectivas. Como tal, essas declara\u00e7\u00f5es s\u00e3o apenas previs\u00f5es e refletem cren\u00e7as e expectativas atuais com rela\u00e7\u00e3o ao futuro, mas s\u00e3o baseadas em suposi\u00e7\u00f5es e est\u00e3o sujeitas a riscos e incertezas e sujeitas a altera\u00e7\u00f5es a qualquer momento. Os eventos ou resultados reais podem diferir materialmente daqueles contidos nas proje\u00e7\u00f5es ou declara\u00e7\u00f5es prospectivas.&nbsp;<\/p>\n<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ###<\/p>\n<p><a target=\"_blank\" href=\"\/pt\/files\/press_releases\/2-11-15_ RHI_NR.pdf\/\">vers\u00e3o impressa<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>A RHI, uma empresa de desenvolvimento em est\u00e1gio inicial localizada em San Antonio, TX, nomeou a Brakke Consulting, Inc. de Dallas, TX para sua nova tecnologia de plataforma, eRapa, com direitos para um portf\u00f3lio completo de pedidos de patentes. eRapa mostra-se muito promissor como o primeiro inibidor de m-Tor da classe na medicina veterin\u00e1ria. Como modulador imunol\u00f3gico citost\u00e1tico, o eRapa tem um amplo espectro de benef\u00edcios potenciais, incluindo: regula\u00e7\u00e3o negativa do ciclo celular no c\u00e2ncer e na autoimunidade, autofagia aprimorada que permite a remo\u00e7\u00e3o de detritos celulares ap\u00f3s trauma ou com envelhecimento avan\u00e7ado, patologia vascular melhorada que permite aumento do fluxo sangu\u00edneo para idosos e \u00f3rg\u00e3os danificados, e uma capacidade de refor\u00e7o imunol\u00f3gico em indiv\u00edduos saud\u00e1veis. A RHI demonstrou seguran\u00e7a e efic\u00e1cia do eRapa em tr\u00eas programas terap\u00eauticos piloto em c\u00e3es e gatos, incluindo Estomatite Gengivo Cr\u00f4nica Felina (FCGS), Disfun\u00e7\u00e3o Cognitiva Canina (CCD) e Dist\u00farbio do Disco Intervertebral (IVDD). Um quarto ensaio cl\u00ednico em oncologia canina est\u00e1 em andamento. Est\u00e1 em curso a interface com o Centro de Medicina Veterin\u00e1ria. \u201cEstamos satisfeitos por ter a Brakke Consulting na equipe para nos ajudar a encontrar um parceiro para o desenvolvimento e comercializa\u00e7\u00e3o da Rapamicina\u201d, disse Randy Goldsmith, CEO da RHI. Para obter mais informa\u00e7\u00f5es sobre esta tecnologia, entre em contato com o Dr. David Goodnight pelo telefone 830-285-1259 ou Ron Brakke pelo telefone 972-243-4033. Sobre a Brakke Consulting H\u00e1 mais de 28 anos a Brakke Consulting oferece solu\u00e7\u00f5es abrangentes para a ind\u00fastria de sa\u00fade animal<\/p>\n<div class=\"view-full-post\"><a href=\"https:\/\/brakkeconsulting.com\/pt\/23927\/\" class=\"view-full-post-btn\">Ver postagem completa<\/a><\/div>\n<p>;<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[],"class_list":["post-23927","post","type-post","status-publish","format-standard","hentry","category-company-news"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>News from Brakke Consulting<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/brakkeconsulting.com\/pt\/23927\/\" \/>\n<meta property=\"og:locale\" content=\"pt_PT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"News from Brakke Consulting\" \/>\n<meta property=\"og:description\" content=\"RHI, an early stage development company located in San Antonio, TX, has appointed Brakke Consulting, Inc. of Dallas, TX for its new platform technology, eRapa, with rights to a full portfolio of patent applications.&nbsp; eRapa shows great promise to be the First-in-Class m-Tor inhibitor in veterinary medicine.&nbsp; As a cytostatic immune modulator, eRapa has a broad spectrum of potential benefits including: cell cycle downregulation in cancer and autoimmunity, enhanced autophagy which enables the removal of cellular debris after trauma or with advanced aging, improved vascular pathology which enables increased blood flow to aged and damaged organs, and an immune boosting capacity in healthy subjects. RHI has demonstrated safety and efficacy of eRapa in three pilot therapeutic programs in dogs and cats including Feline Chronic Gingivo-Stomatitits (FCGS), Canine Cognitive Dysfunction (CCD), and Intervertebral Disc Disorder (IVDD). A fourth clinical trial in canine oncology is underway.&nbsp;&nbsp; Interface with the Center for Veterinary Medicine is underway. &ldquo;We are pleased to have Brakke Consulting on the team to assist us in finding a partner for the further development and commercialization of Rapamycin,&rdquo; says Randy Goldsmith, CEO of RHI. For more information on this technology, contact Dr. David Goodnight at 830-285-1259 or Ron Brakke at 972-243-4033.&nbsp; About Brakke Consulting For more than 28 years, Brakke Consulting has offered comprehensive solutions for the animal health industry,View Full Post;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/brakkeconsulting.com\/pt\/23927\/\" \/>\n<meta property=\"og:site_name\" content=\"Brakke Consulting Website\" \/>\n<meta property=\"article:published_time\" content=\"2015-02-11T18:51:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2018-04-16T14:45:08+00:00\" \/>\n<meta name=\"author\" content=\"Brakke Consulting\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Brakke Consulting\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tempo estimado de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/brakkeconsulting.com\/23927\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/brakkeconsulting.com\/23927\/\"},\"author\":{\"name\":\"Brakke Consulting\",\"@id\":\"https:\/\/brakkeconsulting.com\/#\/schema\/person\/a5d2c4b59040e54bfe8f4f41f77e04d6\"},\"headline\":\"RHI Appoints Brakke Consulting as Exclusive Agent for eRapa (a patent pending formulation of Rapamycin)\",\"datePublished\":\"2015-02-11T18:51:17+00:00\",\"dateModified\":\"2018-04-16T14:45:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/brakkeconsulting.com\/23927\/\"},\"wordCount\":468,\"articleSection\":[\"Company News\"],\"inLanguage\":\"pt-PT\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/brakkeconsulting.com\/23927\/\",\"url\":\"https:\/\/brakkeconsulting.com\/23927\/\",\"name\":\"News from Brakke Consulting\",\"isPartOf\":{\"@id\":\"https:\/\/brakkeconsulting.com\/#website\"},\"datePublished\":\"2015-02-11T18:51:17+00:00\",\"dateModified\":\"2018-04-16T14:45:08+00:00\",\"author\":{\"@id\":\"https:\/\/brakkeconsulting.com\/#\/schema\/person\/a5d2c4b59040e54bfe8f4f41f77e04d6\"},\"breadcrumb\":{\"@id\":\"https:\/\/brakkeconsulting.com\/23927\/#breadcrumb\"},\"inLanguage\":\"pt-PT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/brakkeconsulting.com\/23927\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/brakkeconsulting.com\/23927\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/brakkeconsulting.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"RHI Appoints Brakke Consulting as Exclusive Agent for eRapa (a patent pending formulation of Rapamycin)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/brakkeconsulting.com\/#website\",\"url\":\"https:\/\/brakkeconsulting.com\/\",\"name\":\"Brakke Consulting Website\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/brakkeconsulting.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-PT\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/brakkeconsulting.com\/#\/schema\/person\/a5d2c4b59040e54bfe8f4f41f77e04d6\",\"name\":\"Brakke Consulting\",\"url\":\"https:\/\/brakkeconsulting.com\/pt\/author\/i5ww2018\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Not\u00edcias da Brakke Consulting","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/brakkeconsulting.com\/pt\/23927\/","og_locale":"pt_PT","og_type":"article","og_title":"News from Brakke Consulting","og_description":"RHI, an early stage development company located in San Antonio, TX, has appointed Brakke Consulting, Inc. of Dallas, TX for its new platform technology, eRapa, with rights to a full portfolio of patent applications.&nbsp; eRapa shows great promise to be the First-in-Class m-Tor inhibitor in veterinary medicine.&nbsp; As a cytostatic immune modulator, eRapa has a broad spectrum of potential benefits including: cell cycle downregulation in cancer and autoimmunity, enhanced autophagy which enables the removal of cellular debris after trauma or with advanced aging, improved vascular pathology which enables increased blood flow to aged and damaged organs, and an immune boosting capacity in healthy subjects. RHI has demonstrated safety and efficacy of eRapa in three pilot therapeutic programs in dogs and cats including Feline Chronic Gingivo-Stomatitits (FCGS), Canine Cognitive Dysfunction (CCD), and Intervertebral Disc Disorder (IVDD). A fourth clinical trial in canine oncology is underway.&nbsp;&nbsp; Interface with the Center for Veterinary Medicine is underway. &ldquo;We are pleased to have Brakke Consulting on the team to assist us in finding a partner for the further development and commercialization of Rapamycin,&rdquo; says Randy Goldsmith, CEO of RHI. For more information on this technology, contact Dr. David Goodnight at 830-285-1259 or Ron Brakke at 972-243-4033.&nbsp; About Brakke Consulting For more than 28 years, Brakke Consulting has offered comprehensive solutions for the animal health industry,View Full Post;","og_url":"https:\/\/brakkeconsulting.com\/pt\/23927\/","og_site_name":"Brakke Consulting Website","article_published_time":"2015-02-11T18:51:17+00:00","article_modified_time":"2018-04-16T14:45:08+00:00","author":"Brakke Consulting","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Brakke Consulting","Tempo estimado de leitura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/brakkeconsulting.com\/23927\/#article","isPartOf":{"@id":"https:\/\/brakkeconsulting.com\/23927\/"},"author":{"name":"Brakke Consulting","@id":"https:\/\/brakkeconsulting.com\/#\/schema\/person\/a5d2c4b59040e54bfe8f4f41f77e04d6"},"headline":"RHI Appoints Brakke Consulting as Exclusive Agent for eRapa (a patent pending formulation of Rapamycin)","datePublished":"2015-02-11T18:51:17+00:00","dateModified":"2018-04-16T14:45:08+00:00","mainEntityOfPage":{"@id":"https:\/\/brakkeconsulting.com\/23927\/"},"wordCount":468,"articleSection":["Company News"],"inLanguage":"pt-PT"},{"@type":"WebPage","@id":"https:\/\/brakkeconsulting.com\/23927\/","url":"https:\/\/brakkeconsulting.com\/23927\/","name":"Not\u00edcias da Brakke Consulting","isPartOf":{"@id":"https:\/\/brakkeconsulting.com\/#website"},"datePublished":"2015-02-11T18:51:17+00:00","dateModified":"2018-04-16T14:45:08+00:00","author":{"@id":"https:\/\/brakkeconsulting.com\/#\/schema\/person\/a5d2c4b59040e54bfe8f4f41f77e04d6"},"breadcrumb":{"@id":"https:\/\/brakkeconsulting.com\/23927\/#breadcrumb"},"inLanguage":"pt-PT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/brakkeconsulting.com\/23927\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/brakkeconsulting.com\/23927\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/brakkeconsulting.com\/"},{"@type":"ListItem","position":2,"name":"RHI Appoints Brakke Consulting as Exclusive Agent for eRapa (a patent pending formulation of Rapamycin)"}]},{"@type":"WebSite","@id":"https:\/\/brakkeconsulting.com\/#website","url":"https:\/\/brakkeconsulting.com\/","name":"Site da Brakke Consulting","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/brakkeconsulting.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-PT"},{"@type":"Person","@id":"https:\/\/brakkeconsulting.com\/#\/schema\/person\/a5d2c4b59040e54bfe8f4f41f77e04d6","name":"Brakke Consultoria","url":"https:\/\/brakkeconsulting.com\/pt\/author\/i5ww2018\/"}]}},"_links":{"self":[{"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/posts\/23927","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/comments?post=23927"}],"version-history":[{"count":1,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/posts\/23927\/revisions"}],"predecessor-version":[{"id":25530,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/posts\/23927\/revisions\/25530"}],"wp:attachment":[{"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/media?parent=23927"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/categories?post=23927"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/tags?post=23927"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}